Welcome to our dedicated page for Evommune SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. reported an insider equity transaction by its Chief Financial Officer on a Form 4. On 12/09/2025, 13,290 shares of common stock were withheld at a price of $17.84 per share to cover the officer’s tax obligations tied to the settlement of restricted stock units. After this tax withholding event, the CFO directly beneficially owned 62,510 shares of Evommune common stock.
Evommune, Inc. reported an insider equity transaction by a director and Chief Medical Officer. On 12/09/2025, the insider had 1,478 shares of common stock withheld at a price of $17.84 per share to cover tax withholding obligations tied to the settlement of restricted stock units. After this tax-related withholding, the insider beneficially owns 270,818 shares of Evommune common stock in direct ownership.
Evommune, Inc. reported its first meaningful collaboration revenue while remaining deeply loss-making as it advances inflammatory disease drug candidates EVO756 and EVO301. For the quarter ended September 30, 2025, license revenue was $10.0 million versus none a year earlier, driven mainly by a $10.0 million Maruho milestone, bringing year-to-date license revenue to $13.0 million compared with $7.0 million in 2024.
Total operating expenses rose to $23.3 million for the quarter and $64.4 million for the first nine months, led by research and development spending of $19.6 million in the quarter as clinical programs progressed. The company posted a quarterly net loss of $12.5 million and a nine‑month net loss of $40.6 million, with an accumulated deficit of $192.8 million.
Evommune strengthened its balance sheet with a $65.3 million Series C preferred financing in June 2025 and, after quarter‑end, a $172.5 million initial public offering in November 2025. As of September 30, 2025, it held $26.8 million in cash and cash equivalents and $49.2 million in short‑term investments, and management expects available capital to fund operations for at least twelve months from the financial statement issuance date.
Evommune, Inc. filed a current report to share that it has issued a press release with a business update and its financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company notes that this information is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws and is not automatically included in other SEC filings unless specifically referenced.
Evommune, Inc. (EVMN) reported insider ownership changes tied to its initial public offering. RA Capital–affiliated entities converted Series C Preferred Stock into Common Stock immediately prior to the IPO and also bought additional shares in the offering.
The Fund and RA Capital Nexus Fund III converted preferred stock into 1,517,329 and 691,441 shares of Common Stock, respectively, and then purchased 1,157,096 and 92,904 additional Common shares at $16 per share. These holdings are reported as indirectly owned, with RA Capital Management, L.P., its general partner, and related individuals disclaiming beneficial ownership beyond their pecuniary interests. The reporting persons are identified as both a director affiliate and 10% owner of Evommune.
Evommune, Inc. insider LSP 7 Management B.V., as director of LSP 7 Cooperatief U.A., reported multiple equity transactions dated 11/07/2025. All outstanding shares of Series A, Series B, and Series C preferred stock automatically converted into common stock immediately before Evommune’s initial public offering, for no additional consideration, at fixed ratios for each series. Following these conversions, the reporting person bought an additional 1,562,500 shares of common stock at $16 per share. After the reported transactions, LSP 7 Cooperatief U.A. directly held 4,929,633 shares of Evommune common stock.